Aerami Therapeutics Was A Clinical Stage Biopharmaceutical Company Based In Durhamnorth Carolinafocused On Developing Inhaled Therapies For Severe Cardiopulmonary And Metabolic Conditionsfounded In 2010The Company Aimed To Enhance Treatment Outcomes For Serious Diseases By Combining Precision Medicines With Advanced Delivery Platformstheir Mission Centered On Improving Both Longevity And Quality Of Life For Patients Through Non Invasivetargeted Therapies Aerami S Notable Productaer 901Was An Inhaled Formulation Of Imatinib Designed To Treat Pulmonary Arterial Hypertension And Pulmonary Hypertension Associated With Interstitial Lung Diseasethe Company Also Explored Inhaled Insulin Solutions For Type 1 And Type 2 Diabetespromoting Needle Free Administrationadditionallyaerami Developed Preservative Freesingle Dose Inhaler Systems To Improve Drug Stability And Patient Compliancedespite Raising Significant Fundingaerami Ceased Operations In August 2024
